Yaupon Therapeutics Inc., of Radnor, has named Steve Tullman, the former chief executive of Ception Therapeutics, as its chairman and CEO.
Yaupon's lead product is an experimental treatment for cutaneous T-cell lymphoma. The mechlorethamine gel has been granted "fast-track" status as well as "orphan drug" status by the Food and Drug Administration.
The company said in a statement that it expects to file a New Drug Application with the FDA for the product in mid-2011.
To do so, Tullman said in the statement that he would "build an experienced management team," including bringing in former Ception executives. Ception was acquired by Cephalon Inc. in April 2010.